The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | T-Cell dynamics in response to neoadjuvant atezolizumab in early NSCLC
Filiz Oezkan, MD, University Hospital Essen, Essen, Germany, provides an overview into an analysis of the Phase II LCMC3 (NCT02927301) trial of neoadjuvant atezolizumab in early-stage non-small cell lung cancer (NSCLC), exploring the impact of T-cell dynamics in the tumor and peripheral blood in association with pathologic response. Tumor, blood and lymph node samples were taken prior to treatment and after 2 cycles at surgery. Neoadjuvant atezolizumab in early-stage NSCLC increased specific T-cell clone expansion in the tumor compared with pre-treatment, which was associated with better pathologic response. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
